500 mg [14C]-LX1606
Phase 1Completed 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoid Syndrome
Conditions
Carcinoid Syndrome
Trial Timeline
Aug 1, 2013 → —
NCT ID
NCT01932528About 500 mg [14C]-LX1606
500 mg [14C]-LX1606 is a phase 1 stage product being developed by Lexicon Pharmaceuticals for Carcinoid Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01932528. Target conditions include Carcinoid Syndrome.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01932528 | Phase 1 | Completed |
Competing Products
20 competing products in Carcinoid Syndrome